Literature DB >> 15213843

High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII.

Christian M Schambeck1, Ralf Grossmann, Sarah Zonnur, Mario Berger, Kathleen Teuchert, Alois Spahn, Ulrich Walter.   

Abstract

Theoretically, von Willebrand factor (VWF) should be capable of binding all factor VIII (FVIII), but an unbound FVIII (uFVIII) plasma fraction remains. In patients' status post deep-vein thrombosis (DVT), an altered uFVIII fraction and high FVIII levels might be indicative of dysfunctional FVIII regulation. Out of 928 consecutive DVT patients, 321 were found to have high FVIII levels. After excluding 183 patients with known causes for high FVIII levels, plasma samples with unexplainably high FVIII levels were available from 84 patients. To capture the FVIII-VWF-complex, superparamagnetic polystyrene beads with covalently attached streptavidin were coated with biotinylated anti-rabbit Ig and incubated with rabbit anti-human VWF-Ig. Slowly thawed plasma samples were added to cooled beads, which were then separated by a magnetic particle concentrator. The uFVIII fraction was calculated by dividing the FVIII activity in the supernatant of the FVIII-VWF-complex-free sample by the FVIII activity in the supernatant of the control sample. Additionally, the VWF residuum in the supernatant was determined. Compared to age- and sex-matched blood donors, thrombosis patients showed a significantly higher plasma FVIII/VWF ratio (median: 1.3 vs. 1.0, p<0.001). uFVIII fraction data were adjusted for VWF residuum. After forward stepwise logistic regression, uFVIII had an odds ratio of 0.48 (95% CI 0.34-0.65), i.e. the uFVIII fraction was reduced in thrombosis patients. Analysis of covariance confirmed these results: In thrombosis patients, the estimated mean of the uFVIII fraction was significantly lower (6.34% vs. 7.58%, p<0.001). In conclusion, thrombosis patients with high FVIII levels showed a higher FVIII/VWF ratio, similar to mice with defective FVIII clearance. The clearly reduced uFVIII fraction lends further support to the hypothesis of a modified FVIII clearance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15213843     DOI: 10.1160/TH04-02-0063

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  Haemostatic system in inflammatory bowel diseases: new players in gut inflammation.

Authors:  Franco Scaldaferri; Stefano Lancellotti; Marco Pizzoferrato; Raimondo De Cristofaro
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

2.  High coagulation factor VIII and von Willebrand factor in patients with lymphoma and leukemia.

Authors:  Martin Mohren; Kathleen Jentsch-Ullrich; Michael Koenigsmann; Siegfried Kropf; Enrico Schalk; Gerd Lutze
Journal:  Int J Hematol       Date:  2015-11-26       Impact factor: 2.490

3.  In vitro and in vivo evaluation of the effect of elevated factor VIII on the thrombogenic process.

Authors:  M Golder; J Mewburn; D Lillicrap
Journal:  Thromb Haemost       Date:  2012-11-22       Impact factor: 5.249

4.  Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.

Authors:  S Lalezari; U Martinowitz; J Windyga; M M Enriquez; H Delesen; L Schwartz; I Scharrer
Journal:  Haemophilia       Date:  2013-11-20       Impact factor: 4.287

5.  Candidate SNP markers of reproductive potential are predicted by a significant change in the affinity of TATA-binding protein for human gene promoters.

Authors:  Irina V Chadaeva; Petr M Ponomarenko; Dmitry A Rasskazov; Ekaterina B Sharypova; Elena V Kashina; Dmitry A Zhechev; Irina A Drachkova; Olga V Arkova; Ludmila K Savinkova; Mikhail P Ponomarenko; Nikolay A Kolchanov; Ludmila V Osadchuk; Alexandr V Osadchuk
Journal:  BMC Genomics       Date:  2018-02-09       Impact factor: 3.969

6.  Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients.

Authors:  Kathelijn Fischer; Ronan Pendu; Carina J van Schooten; Karin van Dijk; Cécile V Denis; H Marijke van den Berg; Peter J Lenting
Journal:  PLoS One       Date:  2009-08-25       Impact factor: 3.240

7.  Detection of fibrinogen and coagulation factor VIII in plasma by a quartz crystal microbalance biosensor.

Authors:  Chunyan Yao; Ling Qu; Weiling Fu
Journal:  Sensors (Basel)       Date:  2013-05-24       Impact factor: 3.576

Review 8.  To clear or to fear: An innate perspective on factor VIII immunity.

Authors:  Jesse Derek Lai; Maria Teofana Georgescu; Christine Hough; David Lillicrap
Journal:  Cell Immunol       Date:  2015-10-28       Impact factor: 4.868

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.